Vor Biopharma (VOR)
(Delayed Data from NSDQ)
$0.95 USD
-0.03 (-3.04%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.95 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VOR 0.95 -0.03(-3.04%)
Will VOR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VOR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VOR
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
VOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
Can Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect?
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 295%
Other News for VOR
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Voyager Therapeutics appoints Nathan Jorgensen as CFO
Voyager Therapeutics appoints Jorgensen as CFO
Vor Biopharma Announces Interim Financial Leadership Changes
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)